{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/impetigo/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"8abd7c1c-e4d5-5fc6-9deb-2cfbbee04b6a","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 4310dfc0-babe-447f-8408-4df0173367e5 --><h2>Changes</h2><!-- end field 4310dfc0-babe-447f-8408-4df0173367e5 -->","summary":null,"htmlStringContent":"<!-- begin item 817dd0d0-f5cf-490b-a9f4-ccc4642e947d --><!-- begin field eed523a0-3318-46a9-96ea-eafef7ec5095 --><p><strong>February 2020</strong> – minor update. The treatment recommendations section has has been updated in line with the National Institute for Health and Care Excellence (NICE) guideline <em>Impetigo: antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">NICE, 2020</a>].</p><p><strong>September 2018</strong> — reviewed. A literature search was conducted in July 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. Changes to recommendations include:</p><ul><li>A change in the duration of treatment of mild localized impetigo with fusidic acid from 7 to 5 days based on recommendations by Public Health England to reduce the risk of bacterial resistance.</li></ul><!-- end field eed523a0-3318-46a9-96ea-eafef7ec5095 --><!-- end item 817dd0d0-f5cf-490b-a9f4-ccc4642e947d -->","topic":{"id":"df142ae3-a675-5faa-955f-deba3aa176bc","topicId":"08c2a82c-2e88-477a-a00d-e75b47770e61","topicName":"Impetigo","slug":"impetigo","lastRevised":"Last revised in February 2020","chapters":[{"id":"5d5b7bff-ba78-5008-89df-49963bc208b7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"35862574-df78-5554-bbe6-86275287ef3a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"bc13ef99-c08d-5361-89de-765433a18ce3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8abd7c1c-e4d5-5fc6-9deb-2cfbbee04b6a","slug":"changes","fullItemName":"Changes"},{"id":"5105f48d-40d4-5c74-bec6-af0574471e5a","slug":"update","fullItemName":"Update"}]},{"id":"8c2bfe64-9ced-531b-b641-00b4ff18bd7c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"eaefc2a4-19e1-525e-82f4-dccc7115b2b6","slug":"goals","fullItemName":"Goals"},{"id":"5a84c42b-0cca-52ed-9924-c54417494c01","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5275b616-56f0-5b49-b2df-0cbffee7e3fc","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6ed2c217-68c2-5ecc-8c61-7187fcbead1b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1dec750c-6e33-5adf-ae33-87a7f4a042c2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"abff03ac-c7cc-5fe7-b6de-0871e4a2846a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba37e0a2-65cd-52ec-8992-3299b96c1ea0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9440ce15-e09d-57c4-9ff1-70e323defaf3","slug":"definition","fullItemName":"Definition"},{"id":"605ba802-106d-5b36-93df-7644ebd9231d","slug":"causes","fullItemName":"Causes"},{"id":"863740f1-ab66-5109-bcb1-30ef774d0d2c","slug":"incidence","fullItemName":"Incidence"},{"id":"69d86930-4301-54ce-8d47-133d348f0b7b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"afe26e4f-1499-57be-a412-9d17510303e9","slug":"complications","fullItemName":"Complications"}]},{"id":"cf492669-e436-53c8-b2b7-f369198b6622","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8dee3a55-eaa2-5aab-b6e5-9a89ad394715","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"46b7f694-9523-5232-ad5d-ca6d1dba2c94","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6e579521-48f9-59b3-a8e3-5e8e37473653","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eebe4528-d9d4-5e2e-ab08-fe1255e1564b","fullItemName":"Management","slug":"management","subChapters":[{"id":"3f2b5528-3a31-51ee-9a7c-713b86cf2854","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"60f683cb-4447-5ecd-9b90-245b33e20336","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f5f53214-ec8d-5ca7-8dde-0ef07d26b140","slug":"hydrogen-peroxide","fullItemName":"Hydrogen peroxide"},{"id":"178eb388-927e-59ea-8289-59bd71cf7ae0","slug":"fusidic-acid","fullItemName":"Fusidic acid"},{"id":"7ee4e706-9719-555b-85eb-18477604621b","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"58ff6676-3c7d-5610-98c3-5e6b6b326c5c","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"9983753e-f306-528c-bcad-5c5e37e49831","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4825af9d-eb38-5c45-a29d-40a17e11e044","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"484c3649-34b0-537b-9431-0907ac172480","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e05d1269-8a31-569f-b89a-f9609763db8b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c7093c62-22f3-531b-ab5c-3c222fd9220e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"25fc1ec7-3a38-5636-9e71-37951cbae3e8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7eec7c7-f55f-53ec-afb1-6fa00707cb90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9e2f110a-ec9f-5728-8f52-cb51f2bfe209","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"bc13ef99-c08d-5361-89de-765433a18ce3","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"25d464c7-3985-5176-8d40-a880453962b4","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 1905f2eb-b9fc-4632-ac5f-275b0e1b3a26 --><h3>Previous changes</h3><!-- end field 1905f2eb-b9fc-4632-ac5f-275b0e1b3a26 -->","summary":null,"htmlStringContent":"<!-- begin item 78fcc536-88e0-4fe7-a3e5-1dd15e71958f --><!-- begin field b09756ea-702b-40df-bc6a-6753daad744f --><p><strong>December 2016</strong> — minor update. The dose of clarithromycin for people with severe renal impairment has been clarified, in line with the manufacturer's Summary of Product Characteristics [ABPI, 2016].</p><p><strong>July 2015 </strong>— minor updates:</p><ul><li>Text regarding the basis for prescribing oral erythromycin as an option if there is a history of penicillin allergy has been amended to remove the relative cost of erythromycin compared with clarithromycin.</li><li>The information on the concurrent use of clarithromycin or erythromycin with statins has been clarified.</li></ul><p><strong>July 2014</strong> — minor update. Text changed in prescribing information to reflect the manufacturer's recommendation that topical fucidic acid can be used during pregnancy. It can also be used during breastfeeding but should not be applied to the breast.</p><p><strong>July 2013</strong> — reviewed. A literature search was conducted in June 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>May 2011</strong> — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>August 2010 </strong>— minor update. The Health Protection Agency (HPA) advise that children (and adults) should stay away from school (or work) until the lesions have scabbed over, or for 48 hours after starting antibiotic treatment. Issued in August 2010.</p><p><strong>December 2008 to June 2009</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Retapamulin has been included as a second-line treatment for localized areas of impetigo.</p><p><strong>November 2008</strong> — minor update. Clarithromycin added as an antibiotic option if a person is penicillin allergic. Issued in December 2008.</p><p><strong>September 2008</strong> — minor correction to the Changes section. Issued in September 2008.</p><p><strong>October to December 2005</strong> — reviewed. Validated in March 2006 and issued in May 2006.</p><p><strong>September 2002</strong> — written. Validated in October 2002 and issued in December 2002.</p><!-- end field b09756ea-702b-40df-bc6a-6753daad744f --><!-- end item 78fcc536-88e0-4fe7-a3e5-1dd15e71958f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}